Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

Doctors are seeing an increase in hair loss among Ozempic users due to the stress of rapid weight loss. The condition is ...

About 2% of U.S. adults use GLP-1 drugs, but results vary. Diet, exercise, and mental health remain key to long-term success.

Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...

Novo Nordisk (NVO) is on pace to gap lower at the opening bell today, with shares of the pharma giant plunging up to 30% in ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Discover effective weight loss strategies from Snigdha Baruah, who lost 35 kg without shortcuts, Ozempic, or extreme workouts ...

The Trump administration has pledged to curb rising obesity with school meal reforms and artificial dye bans, though the ...